The Shanghai plant is undergoing a review process in order to be the first US Food and Drug Administration approved site for contrast media (x-ray dyes used to provide contrast) in China. Upon approval, the GE Healthcare plant will be able to supply products globally.

In the next five years, the demand for contrast media in China is expected to grow in double digits. To meet this demand, the company is making provisions today for an increase in production capacity.




Merck KGaA establishes US subsidiary:


German pharmaceuticals group Merck KGaA has established a generic drugs subsidiary, Genpharm, in New York, to provide direct access to customers in the US market.

Quand Medical puts money into UK:


Ontario-based company Quand Medical Corporation has relocated its pioneering high-tech operation to Newcastle, UK. It is developing a system using mobile phone and RFID technology to remind people when to take their medication and to give them more information about the drugs.

PolyPeptide plans expansions:


Denmark-based PolyPeptide Laboratories has announced plans to increase its peptide manufacturing capabilities substantially in both the US and Sweden. The expansion will take place at manufacturing facilities in Torrance, California, and Malmo, Sweden.

Lonza in Singapore joint venture:


An investment arm of the Singapore Economic Development Board, BioOne Capital, is setting up a joint venture with Lonza of Switzerland to build a biopharmaceuticals plant in Singapore. The facility is expected to help drive Singapore’s push to become the biomedical hub of Asia.